Physician profile
Stuart A Kittay
NPI 1871596544
$2,439.06
in general payments reported to CMS, 2019-2025
11 companies · $670 in 2025
The $670 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $107 · 2021: $247 · 2022: $472 · 2023: $155 · 2024: $178 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.14 | 2019-2025 | |
| Leo Pharma INC. | $318.80 | 2022-2025 | Anzupgo, Adbry |
| Pfizer INC. | $312.54 | 2019-2022 | |
| Ucb, INC. | $259.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2022-2025 | |
| Incyte Corporation | $249.99 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $124.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $123.79 | 2021 | |
| Genzyme Corporation | $123.07 | 2021 | |
| Janssen Biotech, INC. | $102.74 | 2023-2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Kittay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.